Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
6
×
Tags
biogen
6
×
biotech
6
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
medicare
6
×
national
national blog main
national top stories
new york blog main
new york top stories
6
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
novartis
alzheimer's disease
cancer
cancer immunotherapy
deals
gene therapy
pfizer
startups
abbvie
celgene
crispr
What
bio
roundup
drug
alzheimer’s
companies
crispr
gene
new
patients
price
prices
remains
talk
acquisitions
albert
allogene
annual
approval
assessed
attention
becker
biggest
billions
biogen’s
biopharmaceutical
biotech
bourla
cancer
ceo
communities
company
conference
convo
different
diversity
dollars
earlier
eaton
esmo
europe
Language
unknown
Current search:
medicare
×
photo
×
biotech
×
" new york top stories "
×
biogen
×
@xconomy.com
5 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More